DSM-Firmenich stock gains support from ongoing share buyback and restructuring

Published on 09/19/2026 at 13:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DSM-Firmenich stock is underpinned by a EUR 500 million share repurchase program announced on February 9, 2026 and active through mid-September 2026. At the same time, the group is cutting about 230 jobs in vitamins and animal nutrition, including 50 roles in Switzerland as reported on September 19, 2026.

Fotorealistisches Duftlabor mit Wissenschaftlern und Destillationsanlagen — dsm-firmenich AG (ISIN CH1216478797) betreibt moderne Duftlabore mit Wissenschaftlern und Analysegeräten für Aromastoffe, Illustration mit AI erstellt.

DSM-Firmenich stock (ISIN CH1216478797) is currently supported by a substantial share repurchase program of EUR 500 million that has been running through the third quarter of 2026, while restructuring in its vitamins and animal nutrition business adds a contrasting operational note for investors as of mid-September 2026.

Buyback program underpins DSM-Firmenich stock

According to Globenewswire on September 15, 2026, DSM-Firmenich confirmed that its ordinary share repurchase program amounts to EUR 500 million aimed at reducing issued capital, complemented by an additional EUR 40 million to cover commitments under share-based compensation plans.

As Globenewswire reported, between September 7, 2026 and September 11, 2026 DSM-Firmenich repurchased a total of 385,000 shares at an average price of EUR 92.07, corresponding to a transaction volume of EUR 35.4 million in that period alone.

The same update states that since the start of the program DSM-Firmenich has repurchased 6,402,212 shares at an average price of EUR 72.91 for a total consideration of EUR 466.8 million, meaning the company has already executed more than 93 percent of its planned EUR 500 million capital reduction by mid-September 2026 and is approaching the intended completion by the end of the third quarter 2026.

Restructuring in vitamins and animal nutrition adds risk factor

As Blick reported on September 19, 2026, DSM-Firmenich plans to cut around 230 jobs globally in its business with vitamins and animal nutrition, citing growing competitive pressure from Chinese producers as a key reason.

According to the same Blick article, 50 of these job reductions will affect facilities in the Swiss canton of Aargau, where DSM-Firmenich employs about 1,000 people in Sisseln and 200 in Kaiseraugst, highlighting that the restructuring also has a tangible impact on its domestic industrial footprint.

For investors, the combination of a nearly completed EUR 500 million share repurchase by the end of the third quarter 2026 and a reduction of roughly 230 positions in a challenged vitamins and animal nutrition segment underlines a dual strategy: balance sheet optimization on the one hand and cost and capacity adjustments on the other to defend margins and competitiveness in the face of intensified Chinese competition.

Stock level and investor perspective

DSM-Firmenich stock is listed on SIX Swiss Exchange in Swiss francs as the primary reference price for international and Swiss investors, with trading levels in mid-September 2026 reflecting ongoing execution of the buyback program while remaining sensitive to news about job cuts and demand trends in vitamins and animal nutrition.

Against this backdrop, the nearly full utilization of the EUR 500 million capital reduction plan by repurchasing 6,402,212 shares at an average price of EUR 72.91, compared with a recent repurchase tranche at EUR 92.07 per share in the week to September 11, 2026, shows that the company has been stepping up purchases at higher price levels as the program nears completion, which can help support DSM-Firmenich stock but also underscores that future support will depend increasingly on operational improvements once the buyback ends.